Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 9,500 Shares of Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) insider Dana Pizzuti sold 9,500 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $45.73, for a total value of $434,435.00. Following the completion of the sale, the insider now owns 27,786 shares of the company’s stock, valued at $1,270,653.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dana Pizzuti also recently made the following trade(s):

• On Monday, April 15th, Dana Pizzuti sold 14,375 shares of Crinetics Pharmaceuticals stock. The shares were sold at an average price of $44.47, for a total value of $639,256.25.

Crinetics Pharmaceuticals Price Performance

CRNX stock opened at $44.87 on Wednesday. The stock has a market capitalization of $3.54 billion, a PE ratio of -11.87 and a beta of 0.64. The company’s 50-day moving average is $46.35 and its 200-day moving average is $41.84. Crinetics Pharmaceuticals, Inc. has a 1 year low of $15.76 and a 1 year high of $53.70.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). The company had revenue of $0.64 million for the quarter, compared to the consensus estimate of $0.20 million. Crinetics Pharmaceuticals had a negative return on equity of 42.50% and a negative net margin of 4,223.27%. Crinetics Pharmaceuticals’s revenue for the quarter was down 76.1% compared to the same quarter last year. During the same period last year, the company earned ($0.85) EPS. On average, analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -3.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in CRNX. Comerica Bank bought a new position in Crinetics Pharmaceuticals in the 1st quarter valued at about $33,000. Quarry LP bought a new position in Crinetics Pharmaceuticals in the 4th quarter valued at about $36,000. AJOVista LLC bought a new position in Crinetics Pharmaceuticals in the 4th quarter valued at about $58,000. HighMark Wealth Management LLC bought a new position in Crinetics Pharmaceuticals in the 4th quarter valued at about $151,000. Finally, Oppenheimer Asset Management Inc. bought a new position in Crinetics Pharmaceuticals in the 1st quarter valued at about $200,000. Institutional investors own 98.51% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on CRNX shares. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Crinetics Pharmaceuticals in a report on Tuesday, June 4th. Jonestrading increased their price target on Crinetics Pharmaceuticals from $52.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th. Morgan Stanley increased their price target on Crinetics Pharmaceuticals from $50.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, May 23rd. Citigroup started coverage on Crinetics Pharmaceuticals in a report on Wednesday, March 6th. They set a “buy” rating and a $68.00 price target for the company. Finally, Oppenheimer increased their price target on Crinetics Pharmaceuticals from $55.00 to $74.00 and gave the stock an “outperform” rating in a report on Tuesday, June 4th. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.